Stockscreener 앱 받기
1.82
1.09%
-0.02
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com India
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus
Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - marketscreener.com
Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in S - GuruFocus
Outlook Therapeutics® Announces SMC Recommendation of - GlobeNewswire
Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients - Stock Titan
Jane Street Group LLC Purchases 15,008 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 - Investing.com Australia
Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Mai - GuruFocus
Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Maintains Buy Rating | OTLK Stock News - GuruFocus
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.
Northern Trust Corp Sells 7,119 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics launches LYTENAVA in Germany and UK By Investing.com - Investing.com South Africa
Outlook Therapeutics® Announces Commercial Launch of - GlobeNewswire
Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD - marketscreener.com
Outlook Therapeutics (OTLK) Launches LYTENAVA in European Markets | OTLK Stock News - GuruFocus
Outlook Therapeutics launches LYTENAVA in Germany and UK - Investing.com Australia
Outlook Therapeutics Launches LYTENAVA For Patients With Wet AMD In Germany And The UK - Nasdaq
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - The Manila Times
Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst - Defense World
Brokers Issue Forecasts for OTLK FY2026 Earnings - Defense World
Metric Analysis: Outlook Therapeutics Inc (OTLK)’s Key Ratios in the Limelight - DWinneX
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $10.20 Average Target Price from Brokerages - Defense World
Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks
Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus
Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus
Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering - marketscreener.com
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire
Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan
Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus
Outlook Therapeutics Reports Improved Financials Amid Challenges - TipRanks
Outlook Therapeutics Plans Share Offering; Stock Declines After Hours - marketscreener.com
Outlook Therapeutics announces public stock offering - Investing.com Australia
Outlook Therapeutics announces public stock offering By Investing.com - Investing.com Canada
Outlook Therapeutics (OTLK) Launches Public Offering of Stock and Warrants | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Comm - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - The Manila Times
Outlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants - Nasdaq
Outlook Therapeutics (OTLK) Sees Price Target Reduced by Guggenheim Analyst | OTLK Stock News - GuruFocus
Outlook Therapeutics (NASDAQ:OTLK) vs. Novavax (NASDAQ:NVAX) Head-To-Head Survey - Defense World
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
1.91%
1.17%
자본화:
|
볼륨(24시간):